HealthEquity, Inc. (NASDAQ:HQY) Holdings Cut by Aureus Asset Management LLC

Aureus Asset Management LLC decreased its stake in HealthEquity, Inc. (NASDAQ:HQY) by 5.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 423,082 shares of the company’s stock after selling 22,909 shares during the quarter. HealthEquity makes up about 2.3% of Aureus Asset Management LLC’s holdings, making the stock its 19th biggest position. Aureus Asset Management LLC’s holdings in HealthEquity were worth $34,629,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of HQY. Price T Rowe Associates Inc. MD raised its holdings in shares of HealthEquity by 7.0% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 51,384 shares of the company’s stock valued at $4,195,000 after purchasing an additional 3,365 shares in the last quarter. GAMMA Investing LLC raised its holdings in shares of HealthEquity by 114.8% during the 2nd quarter. GAMMA Investing LLC now owns 595 shares of the company’s stock valued at $51,000 after purchasing an additional 318 shares in the last quarter. CWM LLC raised its holdings in shares of HealthEquity by 6.9% during the 2nd quarter. CWM LLC now owns 3,958 shares of the company’s stock valued at $341,000 after purchasing an additional 255 shares in the last quarter. SG Americas Securities LLC raised its holdings in shares of HealthEquity by 48.5% during the 2nd quarter. SG Americas Securities LLC now owns 3,798 shares of the company’s stock valued at $327,000 after purchasing an additional 1,241 shares in the last quarter. Finally, Sequoia Financial Advisors LLC bought a new position in shares of HealthEquity during the 2nd quarter valued at $1,122,000. Institutional investors own 99.55% of the company’s stock.

Insider Activity

In other news, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction dated Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total transaction of $684,585.00. Following the sale, the director now directly owns 54,719 shares in the company, valued at approximately $4,540,582.62. The trade was a 13.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Frank Corvino sold 1,247 shares of HealthEquity stock in a transaction dated Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total transaction of $100,084.22. Following the sale, the director now owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 10,536 shares of company stock worth $884,517. Corporate insiders own 2.20% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on HQY. The Goldman Sachs Group began coverage on shares of HealthEquity in a research note on Friday, November 15th. They issued a “neutral” rating and a $108.00 target price on the stock. JMP Securities reiterated a “market outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research note on Wednesday, September 4th. Barrington Research reiterated an “outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research note on Friday, September 20th. Bank of America raised their target price on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. Finally, Deutsche Bank Aktiengesellschaft raised their target price on shares of HealthEquity from $102.00 to $103.00 and gave the company a “buy” rating in a research note on Wednesday, September 4th. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $107.23.

HealthEquity Stock Performance

NASDAQ HQY opened at $101.54 on Monday. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10. The firm has a market capitalization of $8.87 billion, a price-to-earnings ratio of 84.62, a P/E/G ratio of 1.59 and a beta of 0.52. The company’s fifty day moving average is $90.16 and its two-hundred day moving average is $82.81. HealthEquity, Inc. has a 52-week low of $62.10 and a 52-week high of $105.82.

HealthEquity (NASDAQ:HQY) last posted its quarterly earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.50 by $0.16. HealthEquity had a net margin of 9.61% and a return on equity of 9.01%. The company had revenue of $299.93 million for the quarter, compared to analyst estimates of $284.48 million. Equities research analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current year.

HealthEquity Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.